The Power of Centralized and Collaborative Data Analytics Decreasing Proteomics Data Analysis Time by 62% to Scale Breakthroughs in Cancer Care Download full customer story Quick, efficient scale-up of data-driven …
Building a Robust Bioinformatics Infrastructure How streamlining RNA-seq data analysis facilitates groundbreaking Gene & Cell R&D Download full customer story Quick, efficient scale-up of data-driven insights. A Cambridge-based company has …
Accelerate Biotech Innovation Impacts of Modern Transcriptomics Data Analytics Platforms Read the full case study Summary In the past decade, the groundwork has been established for researchers to leverage the …
9 factors you should consider when choosing RNA-seq analysis and visualization software Published on April 20th, 2023 by BigOmics⏱ 11 min read Commercial RNA-seq data analysis software allows researchers, biotechnology, …
In this article, we give an overview of why RNA-seq normalization is essential, and we break down different RNA-seq normalization methods to help you master your next RNA-seq analysis.
The Ultimate Guide to Public RNA-Seq and single-cell RNA-Seq Databases: a Comparative Review Last updated on January 9th, 2024⏱ 13 min read Introduction The wealth of publicly available RNA-sequencing (RNA-seq) and …
How to prepare your RNA-Seq and proteomics data for Omics Playground Published on February 22nd, 2023 by BigOmicsLast updated on February 2nd, 2024⏱ 9 min read Omics Playground is a …
Omics data is becoming ubiquitous both in biological and, increasingly, medical research. Rapid developments in reagents, sequencing technologies and analysis are constantly pushing down costs while increasing the amount of …
Lugano, March 17, 2022 – BigOmics Analytics, a Swiss biodata analytics startup, announces raising additional funding from Eppendorf, a leading life science company that develops and sells instruments, consumables and …
Remix Therapeutics is a Boston-based biotechnology company developing novel small molecule therapies for reprogramming RNA processing and treating disease in entirely new ways. As protein targeting therapies reach the limits …
